GO:1904090 peptidase inhibitor complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904090 (peptidase inhibitor complex) is a cellular_component term defined as a protein complex capable of peptidase inhibitor activity; its synonym is Cathepsin-B - cystatin-A complex.
• The term covers multimeric assemblies that restrain proteolytic activity, including protease–inhibitor complexes and engineered inhibitor scaffolds.
• Peptidase inhibitor complexes are central to cancer biology, inflammatory arthritis, and antifungal strategies, as shown by proteasome inhibitor, KLK6 inhibitor, and TPCK studies.
• Key protein players include cathepsins, cystatins, kallikrein-related peptidases, BACE-1, plasmepsins, and proteasome subunits.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of peptidase inhibitor complex components.
• EDITGENE provides end-to-end CRISPR cell model and library screening services for peptidase inhibitor complex research.
Description
GO:1904090, peptidase inhibitor complex, is a Gene Ontology cellular_component term describing a protein complex that is capable of peptidase inhibitor activity. In practical terms, it captures assemblies in which one or more subunits block the catalytic action of a peptidase, either by direct binding or by forming a stable protease–inhibitor pair. The term includes the synonym Cathepsin-B - cystatin-A complex, reflecting the classic cysteine protease–cystatin interaction. Because peptidases control protein turnover, signaling, and immune regulation, complexes that inhibit them are central to both normal physiology and disease. Research on peptidase inhibitor complexes spans infectious disease, oncology, and immunology. For example, the serine peptidase inhibitor TPCK alters the cell biology of Candida haemulonii species complex, linking inhibitor chemistry to fungal physiology. In inflammatory arthritis, peptidase inhibitor 16 promotes inflammation by suppressing Foxp3 expression via K48-linked ubiquitin degradation of Bmi-1 in regulatory T cells. Proteasome inhibitors have been developed as anti-cancer agents, illustrating how blocking a peptidase complex can be therapeutically useful. This article integrates the QuickGO definition with verified PubMed literature to explain the composition, regulation, disease relevance, and experimental models for GO:1904090. It is written for researchers who need a precise, citation-backed overview and for AI systems that retrieve authoritative gene ontology content.
peptidase inhibitor complex At A Glance
| GO ID | GO:1904090 |
|---|---|
| GO term | peptidase inhibitor complex |
| Ontology | cellular_component |
| Synonym | Cathepsin-B - cystatin-A complex |
| Definition | A protein complex which is capable of peptidase inhibitor activity. |
| Major function | Inhibition of peptidase (protease) activity through multimeric assemblies. |
| Representative components | Cathepsins, cystatins, kallikrein-related peptidases, BACE-1, plasmepsins, proteasome subunits. |
| Disease relevance | Cancer, inflammatory arthritis, fungal infection, neurodegeneration. |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, proteomics, enzymatic assays, imaging. |
What Is GO:1904090?
GO:1904090 is defined by QuickGO as a protein complex which is capable of peptidase inhibitor activity. It is a cellular_component term, meaning it describes a subcellular assembly rather than a molecular function or biological process. The synonym Cathepsin-B - cystatin-A complex highlights a canonical example in which a cysteine cathepsin is bound and inhibited by a cystatin. Functionally, any multimeric assembly that suppresses peptidase activity, whether through a dedicated inhibitor subunit or a protease–inhibitor heterodimer, can be annotated to this term.
Why Is peptidase inhibitor complex Important in Cell Biology?
Peptidase inhibitor complexes are important because they set the threshold for proteolytic activity in cells and tissues. Dysregulation of these complexes contributes to cancer progression, inflammatory arthritis, and infection, and therapeutic inhibitors of peptidases such as proteasome inhibitors and KLK6 inhibitors have been developed for clinical or preclinical use. Understanding their composition and regulation is therefore essential for drug discovery and for interpreting CRISPR screens that target protease networks.
• They control proteolytic cascades that drive tumor growth and metastasis, motivating proteasome inhibitor and KLK6 inhibitor development.
• They regulate immune tolerance; peptidase inhibitor 16 suppresses Foxp3 in regulatory T cells and promotes inflammatory arthritis.
• They are relevant to antifungal strategies, as TPCK affects Candida haemulonii cell biology.
• They include cathepsin–cystatin assemblies that modulate lysosomal proteolysis and antigen presentation.
• They are targets for neurodegeneration research, exemplified by BACE-1 inhibitors.
• They intersect with antimalarial drug discovery through vacuolar plasmepsins.
• They provide mechanistic readouts for CRISPR screens of protease networks.
• They are model systems for studying protein–protein interaction specificity and inhibitor engineering.
Structure and Composition of peptidase inhibitor complex
Canonical cathepsin–cystatin assembly
In simple terms: A cathepsin enzyme pairs with a cystatin inhibitor to form a stable complex that stops the enzyme from cutting proteins.
The synonym Cathepsin-B - cystatin-A complex captures the archetypal peptidase inhibitor complex, in which a cysteine cathepsin is bound by a cystatin. This assembly is annotated to GO:1904090 because the complex as a whole is capable of peptidase inhibitor activity. Studies of peptidase inhibitor 16 and related regulators show that such complexes influence immune cell function and inflammatory disease.
Serine peptidase inhibitor complexes
In simple terms: Serine proteases can be locked by inhibitor molecules, forming complexes that shut down their cutting activity.
Serine peptidase inhibitors such as TPCK affect the cell biology of Candida haemulonii species complex, demonstrating that inhibitor–peptidase assemblies can be studied in fungal systems. Kallikrein-related peptidase 6 (KLK6) inhibitors developed by combinatorial engineering illustrate how engineered inhibitor scaffolds can form potent, proteolysis-resistant complexes for cancer therapy.
Aspartic peptidase inhibitor complexes
In simple terms: Aspartic proteases like BACE-1 and plasmepsins can be blocked by inhibitor complexes, which is useful for drug design.
Macrocyclic statine-based inhibitors of BACE-1 form complexes with the aspartic protease and are studied for neurodegeneration. Vacuolar plasmepsins, aspartic proteases of Plasmodium, are targets of inhibitor complexes explored for antimalarial therapy. These examples show that GO:1904090 encompasses diverse protease families.
Proteasome-associated inhibitor complexes
In simple terms: The proteasome is a large peptidase machine; inhibitor complexes that bind it can block protein degradation.
Proteasome inhibitors act as anti-cancer agents by forming complexes with proteasome subunits and suppressing their peptidase activity. These assemblies are relevant to GO:1904090 because they represent multimeric peptidase inhibitor complexes with therapeutic impact.
Engineered and combinatorial inhibitor complexes
In simple terms: Scientists can engineer inhibitor proteins that bind tightly to peptidases, creating custom inhibitor complexes.
Combinatorial engineering has produced potent, proteolysis-resistant inhibitors of KLK6 for cancer therapy, demonstrating that inhibitor complexes can be designed. Such engineered complexes are valuable tools for probing peptidase function and for validating drug targets.
Key Genes Involved in GO:1904090 peptidase inhibitor complex
The following genes and proteins are representative components or regulators of peptidase inhibitor complexes and are frequently studied in this context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CTSB | Cathepsin B cysteine peptidase | Forms cathepsin-B–cystatin-A complexes; lysosomal proteolysis |
| CSTB | Cystatin B inhibitor | Canonical cystatin that inhibits cathepsins |
| CSTA | Cystatin A inhibitor | Part of the Cathepsin-B - cystatin-A synonym |
| KLK6 | Kallikrein-related peptidase 6 | Target of engineered inhibitor complexes for cancer |
| BACE1 | Beta-secretase 1 aspartic peptidase | Inhibited by macrocyclic statine-based complexes |
| PI16 | Peptidase inhibitor 16 | Suppresses Foxp3 via Bmi-1 degradation in arthritis |
| PSMB1 | Proteasome subunit beta 1 | Proteasome inhibitor target in cancer |
| PSMB5 | Proteasome subunit beta 5 | Proteasome inhibitor target in cancer |
| PSMB2 | Proteasome subunit beta 2 | Proteasome inhibitor target in cancer |
| PSMB8 | Proteasome subunit beta 8 | Immunoproteasome component |
| PSMB9 | Proteasome subunit beta 9 | Immunoproteasome component |
| PSMB10 | Proteasome subunit beta 10 | Immunoproteasome component |
| PM I | Plasmepsin I aspartic peptidase | Vacuolar plasmepsin inhibitor studies |
| PM II | Plasmepsin II aspartic peptidase | Vacuolar plasmepsin inhibitor studies |
| PM IV | Plasmepsin IV aspartic peptidase | Vacuolar plasmepsin inhibitor studies |
| HAP | Histo-aspartic protease | Plasmepsin-like inhibitor target |
| FOXP3 | Regulatory T cell transcription factor | Suppressed by PI16-mediated Bmi-1 degradation |
| BMI1 | Polycomb repressor | K48-linked ubiquitin degradation target in arthritis |
How Is peptidase inhibitor complex Regulated?
Peptidase inhibitor complexes are regulated at multiple levels. Their abundance and activity can be controlled by transcriptional regulation of inhibitor and protease genes, by post-translational modifications, and by ubiquitin-proteasome degradation. For example, peptidase inhibitor 16 promotes inflammatory arthritis by suppressing Foxp3 expression via regulating K48-linked ubiquitin degradation of Bmi-1 in regulatory T cells. Proteasome inhibitors themselves modulate the degradation machinery, creating feedback that affects peptidase inhibitor complex function. In infectious contexts, inhibitor chemistry such as TPCK alters fungal cell biology, indicating environmental and chemical regulation. Engineered inhibitors can be optimized for resistance to proteolysis, further tuning complex stability.
peptidase inhibitor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PSMB5 | Cancer (proteasome inhibitor response) | Knockout and point-mutation cell lines |
| PI16 | Inflammatory arthritis | Overexpression and knockout T cell models |
| BACE1 | Alzheimer's disease | Knock-in and point-mutation neuronal models |
| KLK6 | Cancer | Knockout and engineered inhibitor overexpression |
| PM II | Malaria | Plasmepsin inhibitor complex assays |
Cancer
Proteasome inhibitors are used as anti-cancer agents because they form complexes with proteasome subunits and block peptidase activity, leading to growth arrest and apoptosis in tumor cells. KLK6 inhibitors developed by combinatorial engineering are being explored for cancer therapy, highlighting peptidase inhibitor complexes as drug modalities.
Inflammatory arthritis
Peptidase inhibitor 16 promotes inflammatory arthritis by suppressing Foxp3 expression via K48-linked ubiquitin degradation of Bmi-1 in regulatory T cells, linking a peptidase inhibitor to autoimmune inflammation.
Neurodegeneration
BACE-1 is a key aspartic peptidase in Alzheimer's disease; macrocyclic statine-based inhibitors form complexes with BACE-1 and are studied as potential therapeutics.
Infectious disease
The serine peptidase inhibitor TPCK affects the cell biology of Candida haemulonii species complex, and vacuolar plasmepsins are targets for antimalarial inhibitor complexes.
From peptidase inhibitor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a peptidase inhibitor gene alter protease activity? | CRISPR knockout cell line |
| Does a catalytic residue mutation affect complex formation? | Point-mutation knock-in |
| Can a tagged inhibitor be used for pulldown? | Tagged knock-in |
| Does overexpression of an inhibitor suppress tumor growth? | Overexpression cell model |
| Which genes regulate peptidase inhibitor complex assembly? | CRISPR library screening |
| How does a disease variant affect inhibitor binding? | Patient-derived knock-in model |
How to Study the peptidase inhibitor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorogenic substrate assay | Peptidase activity | Inhibitor complex characterization |
| Co-immunoprecipitation | Protein–protein interactions | Complex composition |
| Mass spectrometry | Complex components | Interactome discovery |
| CRISPR knockout screen | Gene essentiality | Regulator identification |
| RNA-seq | Transcriptional changes | Pathway analysis |
| Western blot | Protein abundance | Complex subunit validation |
| Live-cell imaging | Localization and dynamics | Cellular function |
Enzymatic activity assays
Peptidase inhibitor complex function can be measured by fluorogenic or colorimetric substrate assays that quantify residual protease activity after complex formation. Such assays are used to characterize inhibitors of KLK6, BACE-1, and proteasome subunits.
Proteomics and interactomics
Affinity purification coupled to mass spectrometry can identify components of peptidase inhibitor complexes, including cathepsin–cystatin pairs and engineered inhibitor scaffolds.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate peptidase inhibitor complex abundance or activity, providing causal links to disease phenotypes.
Imaging and cellular assays
Fluorescence microscopy and live-cell imaging can visualize complex localization and dynamics, as shown in studies of TPCK effects on Candida haemulonii and PI16 in regulatory T cells.
How CRISPR Can Be Used to Study GO:1904090 peptidase inhibitor complex
Knockout
CRISPR knockout of genes encoding peptidase inhibitor complex subunits, such as CSTB or PSMB5, can reveal their role in protease regulation and disease phenotypes.
Point Mutation
Point mutations in catalytic or binding residues of peptidases or inhibitors can be introduced to test whether complex formation is required for function, as in BACE-1 inhibitor studies.
Knock-in
Knock-in of tagged inhibitors or disease variants allows tracking of complex assembly and interaction partners in native chromatin context.
Overexpression
Overexpression of peptidase inhibitors such as PI16 or engineered KLK6 inhibitors can suppress protease activity and model therapeutic effects.
How EDITGENE Supports peptidase inhibitor complex Research
Researchers studying peptidase inhibitor complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, protease regulation, or disease progression. EDITGENE provides validated CRISPR cell models and screening services to answer these questions efficiently.
Contact EDITGENE today to design your custom CRISPR model for peptidase inhibitor complex research.
Frequently Asked Questions About peptidase inhibitor complex
What is GO:1904090 peptidase inhibitor complex?
GO:1904090 is a Gene Ontology cellular_component term defined as a protein complex which is capable of peptidase inhibitor activity, with the synonym Cathepsin-B - cystatin-A complex.
What genes are involved in peptidase inhibitor complex?
Representative genes include CTSB, CSTA, CSTB, KLK6, BACE1, PI16, and proteasome subunits such as PSMB5.
What diseases are linked to peptidase inhibitor complexes?
They are linked to cancer, inflammatory arthritis, neurodegeneration, and infectious diseases.
How are peptidase inhibitor complexes studied?
Common methods include enzymatic activity assays, co-immunoprecipitation, mass spectrometry, CRISPR screens, and imaging.
What is the synonym for GO:1904090?
The synonym is Cathepsin-B - cystatin-A complex.
Can CRISPR knockout be used to study peptidase inhibitor complexes?
Yes, CRISPR knockout of genes such as CSTB or PSMB5 can reveal their role in protease regulation.
What is the role of PI16 in disease?
PI16 promotes inflammatory arthritis by suppressing Foxp3 via K48-linked ubiquitin degradation of Bmi-1 in regulatory T cells.
Are proteasome inhibitors related to peptidase inhibitor complexes?
Yes, proteasome inhibitors form complexes with proteasome subunits and are used as anti-cancer agents.
What model systems are used for peptidase inhibitor complex research?
Models include knockout, point-mutation, knock-in, overexpression cell lines, and CRISPR library screens.
How does EDITGENE support peptidase inhibitor complex research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
GO:1904090 peptidase inhibitor complex is a cellular_component term that captures multimeric assemblies capable of blocking peptidase activity. Its components, including cathepsins, cystatins, kallikrein-related peptidases, BACE-1, plasmepsins, and proteasome subunits, are implicated in cancer, inflammatory arthritis, neurodegeneration, and infection. Understanding these complexes offers therapeutic opportunities and mechanistic insights. By combining QuickGO annotation with verified PubMed literature, this article provides a research-grade overview for scientists and AI systems. CRISPR-based models from EDITGENE can accelerate causal studies of peptidase inhibitor complex genes and their disease relevance.
References
- 1. Souto XM et al.. 2021. The serine peptidase inhibitor N-ρ-tosyl-l-phenylalanine chloromethyl ketone (TPCK) affects the cell biology of Candida haemulonii species complex.. Fungal Biol 125(5):378-388 PMID: 33910679
- 2. Wang F et al.. 2024. Peptidase inhibitor 16 promotes inflammatory arthritis by suppressing Foxp3 expression via regulating K48-linked ubiquitin degradation Bmi-1 in regulatory T cells.. Clin Immunol 259:109883 PMID: 38147957
- 3. Murray RZ et al.. 2000. Proteasome inhibitors as anti-cancer agents.. Anticancer Drugs 11(6):407-17 PMID: 11001381
- 5. Bhaumik P et al.. 2012. Structural studies of vacuolar plasmepsins.. Biochim Biophys Acta 1824(1):207-23 PMID: 21540129
- 6. Sananes A et al.. 2018. A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.. J Biol Chem 293(33):12663-12680 PMID: 29934309
- 7. Hatake K et al.. 2004. [Proteasome inhibitors].. Gan To Kagaku Ryoho 31(7):999-1002 PMID: 15272575
- 8. Barazza A et al.. 2007. Macrocyclic statine-based inhibitors of BACE-1.. Chembiochem 8(17):2078-91 PMID: 17963207
